[go: up one dir, main page]

MA28677B1 - N-(2-benzyl) -2-phenylbutanamides modulant le recepteur d'androgene - Google Patents

N-(2-benzyl) -2-phenylbutanamides modulant le recepteur d'androgene

Info

Publication number
MA28677B1
MA28677B1 MA29551A MA29551A MA28677B1 MA 28677 B1 MA28677 B1 MA 28677B1 MA 29551 A MA29551 A MA 29551A MA 29551 A MA29551 A MA 29551A MA 28677 B1 MA28677 B1 MA 28677B1
Authority
MA
Morocco
Prior art keywords
bone
compounds
androgen receptor
disease
cancer
Prior art date
Application number
MA29551A
Other languages
English (en)
Inventor
Barbara Hanney
Yuntae Kim
Michael R Krout
Robert S Meissner
Helen J Mitchell
Jeffrey Musselman
James J Perkins
Jiabing Wang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA28677B1 publication Critical patent/MA28677B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EXTRAIT Les composés de la formule développée I sont des modulateurs de récepteur androgène (AR) à sélectivité tissulaire. Ces composés sont utiles dans le renforcement de la tonicité musculaire affaiblie et le traitement des conditions provoquées par la déficience en androgènes ou qui peuvent être améliorées par l'administration d'androgènes. y compris l'ostéoporose. l'ostéopénie. l'ostéoporose induite par les glucocorticoïdes. la parodontopathie. la fracture de l'os, les lésions de l'os à la suite de chirurgie osseuse reconstructive. la sarcopénie. la fragilité, le vieillissement de la peau, l'hypogénitalisme masculin, les symptômes post-ménopausiques chez les femmes, l'athérosclérose, l'hypercholestérolémie. l'hyperlipidémie. l'obésité, l'anémie aplasique et autres troubles hématopoïetiques. l'arthrite inflammatoire et la réparation des articulations, le dépérissement dû au VIH. le cancer de la prostate, l'hyperplasie prostatique bénigne (BPH). l'adiposité abdominale, le syndrome métabolique, le diabète de type II. la cachexie due au cancer, la maladie d'Alzheimer. les dystrophies musculaires, le déficit cognitif. le dysfonctionnement sexuel, les apnées du sommeil, la dépression, l'insuffisance ovarienne prématurée, et les maladies auto-immunes. seuls ou en combinaison avec d'autres agents actifs.
MA29551A 2004-06-07 2006-12-25 N-(2-benzyl) -2-phenylbutanamides modulant le recepteur d'androgene MA28677B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57769804P 2004-06-07 2004-06-07

Publications (1)

Publication Number Publication Date
MA28677B1 true MA28677B1 (fr) 2007-06-01

Family

ID=35415107

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29551A MA28677B1 (fr) 2004-06-07 2006-12-25 N-(2-benzyl) -2-phenylbutanamides modulant le recepteur d'androgene

Country Status (24)

Country Link
US (3) US7629367B2 (fr)
EP (1) EP1755572B1 (fr)
JP (1) JP4881865B2 (fr)
CN (1) CN1976902A (fr)
AR (1) AR049140A1 (fr)
AT (1) ATE545631T1 (fr)
AU (1) AU2005251766B9 (fr)
BR (1) BRPI0511862A (fr)
CA (1) CA2569124C (fr)
CR (1) CR8777A (fr)
EC (1) ECSP067061A (fr)
IL (1) IL179843A0 (fr)
MA (1) MA28677B1 (fr)
MX (1) MXPA06014235A (fr)
MY (1) MY147997A (fr)
NO (1) NO20070085L (fr)
NZ (1) NZ551738A (fr)
PE (1) PE20060401A1 (fr)
RU (1) RU2378255C2 (fr)
SG (1) SG169398A1 (fr)
TW (1) TW200610755A (fr)
UA (1) UA87854C2 (fr)
WO (1) WO2005120477A2 (fr)
ZA (1) ZA200609673B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CN101052398A (zh) * 2004-10-29 2007-10-10 默克公司 作为雄激素受体调节剂的n－(吡啶－3－基)－2－苯基丁酰胺
CA2616184A1 (fr) * 2005-08-02 2007-02-08 Merck & Co., Inc. N-(pyridin-4-yl)-2-phenylbutanamides en tant que modulateurs du recepteur androgene
KR20080089461A (ko) * 2005-12-30 2008-10-06 랜박시 래보러터리스 리미티드 무스카린 수용체 길항제
CA2666769A1 (fr) * 2006-10-18 2008-04-24 Merck & Co., Inc. 2-hydroxy-2-phenyl/thiophenylpropionamides en tant que modulateurs de recepteur d'androgene
KR101595238B1 (ko) 2007-12-21 2016-02-18 리간드 파마슈티칼스 인코포레이티드 선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
JPWO2009136629A1 (ja) * 2008-05-09 2011-09-08 あすか製薬株式会社 生活習慣病予防・治療剤
JP2013528223A (ja) 2010-06-10 2013-07-08 アラゴン ファーマシューティカルズ，インク． エストロゲン受容体モジュレーターおよびその用途
US8845733B2 (en) 2010-06-24 2014-09-30 DePuy Synthes Products, LLC Lateral spondylolisthesis reduction cage
FR2982261B1 (fr) * 2011-11-04 2014-06-13 Galderma Res & Dev Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
CN103288669B (zh) * 2013-07-01 2015-06-24 南开大学 一种阿卓乳酸酰胺衍生物及应用
WO2015048246A1 (fr) * 2013-09-27 2015-04-02 The Board Of Trustees Of The University Of Illinois Inhibiteurs tétra-aryle-cyclobutane de l'action du récepteur des androgènes pour le traitement d'un cancer réfractaire aux hormones
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
CN107735085B (zh) * 2015-04-21 2021-05-14 Gtx公司 选择性雄激素受体降解剂(sard)配体和其使用方法
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
MX2020012066A (es) 2018-05-14 2021-04-28 Nuvation Bio Inc Compuestos anticancerígenos dirigidos a los receptores hormonales nucleares.
WO2020048826A1 (fr) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft Composés de la 1-oxa-3,9-diazaspiro[5.5]undécan-2-one substituée en position 5
US12202815B2 (en) 2018-09-05 2025-01-21 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CA3133929A1 (fr) 2019-04-19 2020-10-22 Lin Zhi Formes cristallines et procedes de production de formes cristallines d'un compose
MX2021013774A (es) 2019-05-14 2021-12-10 Nuvation Bio Inc Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
US20210024636A1 (en) * 2019-07-26 2021-01-28 Chemistryrx Compositions and methods for treating sexual dysfunction
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
IL306010A (en) 2021-03-23 2023-11-01 Nuvation Bio Inc Anticancer compounds against the nuclear hormone receptor
AU2022269568A1 (en) 2021-05-03 2023-11-16 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113816900B (zh) * 2021-10-18 2024-06-25 宁夏瑞泰科技股份有限公司 一种2-氯-5-甲基吡啶-3-甲醛的合成方法

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809965A (en) 1956-04-30 1957-10-15 Dow Chemical Co Phthalides
CA777769A (en) 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
FR2531088B1 (fr) 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
GB8332704D0 (en) 1983-12-07 1984-01-11 Pfizer Ltd Growth promotants for animals
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
GB8726179D0 (en) * 1987-11-09 1987-12-16 Fujisawa Pharmaceutical Co Heterocyclic derivatives
CA1339805C (fr) 1988-01-20 1998-04-07 Yasuo Isomura Acide (cycloalkylamino) methylenebis phosphonique et medicaments le contenant comme ingredients actif
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5019651A (en) 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5283241A (en) 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5583130A (en) 1992-09-25 1996-12-10 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5317017A (en) 1992-09-30 1994-05-31 Merck & Co., Inc. N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release
US5374721A (en) 1992-10-14 1994-12-20 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
AU676525B2 (en) 1992-11-06 1997-03-13 Merck & Co., Inc. Substituted dipeptide analogs promote release of growth hormone
US5536716A (en) 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
RO115804B1 (ro) 1992-12-11 2000-06-30 Merck & Co Inc Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora
US5284841A (en) 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5430144A (en) 1993-07-26 1995-07-04 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5434261A (en) 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5952281A (en) 1993-08-04 1999-09-14 Colgate Palmolive Company Aqueous cleaning composition which may be in microemulsion form containing a silicone antifoam agent
US5510517A (en) 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
TW257765B (fr) 1993-08-25 1995-09-21 Merck & Co Inc
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
DE4332384A1 (de) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
US5545735A (en) 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
FI961681A7 (fi) 1993-10-19 1996-06-12 Merck & Co Inc Bisfosfonaattien ja kasvuhormoonin eritystä lisäävien aineiden yhdiste lmä
US5438136A (en) 1993-11-02 1995-08-01 Merck & Co., Inc. Benzo-fused macrocycles promote release of growth hormone
CZ134296A3 (en) 1993-11-09 1996-12-11 Merck & Co Inc Piperidine, pyrrolidine and hexahydro-1h-azepine derivatives, process of their preparation and pharmaceutical compositions containing thereof
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5494919A (en) 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
EP0730578A4 (fr) 1993-11-24 1997-10-08 Merck & Co Inc Composes contenant un groupe indolyle et leur utilisation pour favoriser la liberation d'hormones(s) de croissance
WO1995016675A1 (fr) 1993-12-13 1995-06-22 Merck & Co., Inc. Lactames benzo condenses favorisant la liberation de l'hormone de croissance
US5606054A (en) 1993-12-14 1997-02-25 Merck & Co., Inc. Heterocyclic-fused lactams promote release of growth hormone
BR9408377A (pt) 1993-12-23 1997-08-19 Novo Nordisk As Composto composição farmacêutica processo para estimular a liberação de hormônio de crescimento da pituitária e uso do composto
US5854211A (en) 1993-12-23 1998-12-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
EP0760658B1 (fr) 1994-05-27 2002-11-13 Merck & Co. Inc. Composes inhibiteurs de la resorption osseuse induite par osteoclaste
WO1995034311A1 (fr) 1994-06-13 1995-12-21 Merck & Co., Inc. Compose de piperazine provoquant la liberation de l'hormone de croissance
PL318199A1 (en) 1994-06-29 1997-05-26 Smithkline Beecham Corp Antagonists of vitronectin receptors
WO1996000574A1 (fr) 1994-06-29 1996-01-11 Smithkline Beecham Corporation Antagonistes du recepteur de la vibronectine
AU3128195A (en) 1994-07-20 1996-02-16 Merck & Co., Inc. Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone
US5494920A (en) 1994-08-22 1996-02-27 Eli Lilly And Company Methods of inhibiting viral replication
WO1996006087A1 (fr) 1994-08-22 1996-02-29 Smithkline Beecham Corporation Composes bicycliques
US5736357A (en) 1994-10-27 1998-04-07 Arris Pharmaceutical Cathespin O protease
US6544767B1 (en) 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
DE19504379A1 (de) 1995-02-10 1996-08-14 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate sowie sie enthaltende pharmazeutische Präparate
WO1996026190A1 (fr) 1995-02-22 1996-08-29 Smithkline Beecham Corporation Antagonistes des recepteurs a l'integrine
US5710159A (en) 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
WO1997001540A1 (fr) 1995-06-29 1997-01-16 Smithkline Beecham Corporation Antagonistes du recepteur de l'integrine
US6008213A (en) 1995-06-29 1999-12-28 Smithkline Beecham Corporation Integrin receptor antagonists
ATE203234T1 (de) 1995-08-30 2001-08-15 Searle & Co Meta-guanidine, harnstoff, thioharnstoff oder azacyklische aminobenzoesäure-derivate als integrin antagonisten
US6204293B1 (en) 1995-11-06 2001-03-20 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
PT814782E (pt) 1995-12-22 2003-04-30 Nissan Chemical Ind Ltd Composicao farmaceutica estabilizada com um agente basico
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
BR9612381A (pt) 1995-12-29 1999-07-13 Smithkline Beecham Corp Antagonistas receptores vitronectina
TR199801255T2 (xx) 1995-12-29 1998-10-21 Smithkline Beecham Corporation Vitronektin resept�r antagonistleri.
BR9612327A (pt) 1995-12-29 1999-07-13 Smithkline Beecham Corp Antagonistas receptores de vitronectina
EP0796855B1 (fr) 1996-03-20 2002-02-06 Hoechst Aktiengesellschaft Inhibiteurs de la résorption osseuse et antagonistes du récepteur de la vitronectine
DK0888292T3 (da) 1996-03-20 2002-02-18 Genentech Inc Tricykliske forbindelser med virkning over for integriner, især alphavbeta3 integriner, fremgangsmåde til deres fremstilling, mellemprodukter deraf, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf
ES2162676T3 (es) 1996-03-29 2002-01-01 Searle & Co Derivados de fenileno sustituidos en meta y su uso como antagonistas o inhibidores de integrina alfav,beta3.
ATE203515T1 (de) 1996-03-29 2001-08-15 Searle & Co Meta-substituierte phenylsulphonamidderivate
PT889875E (pt) 1996-03-29 2001-10-30 Searle & Co Derivados de acidos ciclopropilalcanoicos
CA2250690A1 (fr) 1996-03-29 1997-10-09 G.D. Searle & Co. Derives de l'acide cinnamique et leur utilisation comme antagonistes de l'integrine
US5925655A (en) 1996-04-10 1999-07-20 Merck & Co., Inc. αv β3 antagonists
PL330915A1 (en) 1996-06-28 1999-06-07 Merck Patent Gmbh Phenylaniline derivatives as inhibitors of integrin
DE19629816A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629817A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US5981546A (en) 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
UA60311C2 (uk) 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
EP0946180A4 (fr) 1996-10-07 2003-07-23 Smithkline Beecham Corp Procede de stimulation de la formation osseuse
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
ATE342262T1 (de) 1996-11-27 2006-11-15 Bristol Myers Squibb Pharma Co Neue integrin rezeptor antagonisten
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
CO4920232A1 (es) 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
DE19705450A1 (de) 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
EP1000031A4 (fr) 1997-07-25 2001-08-16 Smithkline Beecham Corp Antagonistes du recepteur de vitronectine
WO1999006049A1 (fr) 1997-08-04 1999-02-11 Smithkline Beecham Corporation Antagonistes du recepteur de l'integrine
WO1999011626A1 (fr) 1997-09-04 1999-03-11 Smithkline Beecham Corporation Antagonistes des recepteurs d'integrines
PE122699A1 (es) 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina
WO1999015170A1 (fr) 1997-09-24 1999-04-01 Smithkline Beecham Corporation Antagoniste du recepteur de vitronectine
KR20010024249A (ko) 1997-09-24 2001-03-26 스튜어트 알. 수터 비트로넥틴 수용체 길항제
FR2768736B1 (fr) 1997-09-24 2000-05-26 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
EP1049693A1 (fr) 1997-11-26 2000-11-08 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES ET 1,3,4-OXADIAZOLES UTILISES COMME ANTAGONISTES DE $g(a) v?$g(b) 3?
WO1999030709A1 (fr) 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
US6066648A (en) 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
KR20030048081A (ko) 1997-12-17 2003-06-18 머크 앤드 캄파니 인코포레이티드 인테그린 수용체 길항제를 포함하는 약제학적 조성물
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
AU738452B2 (en) 1997-12-17 2001-09-20 Merck & Co., Inc. Integrin receptor antagonists
EP0933367A1 (fr) 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Dérivés d'acylguanidine comme inhibiteurs de résorbtion osseuse et comme antagonistes de récepteur vitronectine
AU1687699A (en) 1997-12-25 1999-07-19 Yamanouchi Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives
SI0928793T1 (en) 1998-01-02 2002-10-31 F. Hoffmann-La Roche Ag Thiazole derivatives
EP0928790B1 (fr) 1998-01-02 2003-03-05 F. Hoffmann-La Roche Ag Dérivés du thiazole
CA2318221A1 (fr) 1998-01-23 1999-07-29 Aventis Pharma Deutschland Gmbh Nouveaux derives de sulfamide comme inhibiteurs de la resorption osseuse et comme inhibiteurs de l'adherence cellulaire
ZA994406B (en) 1998-03-04 2000-02-11 Searle & Co Meta-azacyclic amino benzoic acid and derivatives thereof.
OA12189A (en) 1998-03-10 2006-05-09 Smithkline Beecham Corp Vitronectin receptor antagonists.
WO1999052872A1 (fr) 1998-04-09 1999-10-21 Meiji Seika Kaisha, Ltd. DERIVES D'AMINOPIPERIDINE COMME ANTAGONISTES D'INTEGRINE αvβ¿3?
IL138677A0 (en) 1998-04-10 2001-10-31 Searle & Co Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
AU3561099A (en) 1998-04-14 1999-11-01 American Home Products Corporation Acylresorcinol derivatives as selective vitronectin receptor inhibitors
EP0960882A1 (fr) 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Acylguanidines de thienyl et leur utilisation comme inhibiteurs de la résorptionosseuse et comme antagonistes du récepteur de la vitronectine
AU4385399A (en) 1998-06-29 2000-01-17 Biochem Pharma Inc. Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer
AR019190A1 (es) 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
AU747784B2 (en) 1998-07-29 2002-05-23 Merck & Co., Inc. Integrin receptor antagonists
JP2002522540A (ja) 1998-08-13 2002-07-23 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
GB9828442D0 (en) * 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
EP1204323B1 (fr) 1999-08-18 2004-07-14 Aventis CropScience GmbH Fongicides
WO2001017562A1 (fr) 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Agents promoteurs de l'osteogenese
AU779855B2 (en) 2000-01-06 2005-02-17 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
EP1272467A4 (fr) 2000-04-06 2003-05-07 Merck Frosst Canada Inc Inhibiteurs de proteases a cysteine de type cathepsines
DE60140495D1 (de) 2000-05-31 2009-12-24 Santen Pharmaceutical Co Ltd 1-Ä(adamantyl)alkylÜ-3-Ä(pyridinyl)alkylÜHarnstoff-Verbindungen als TNF-.alpha Hemmer zur Behandlung von Autoimmunerkrankungen
EP1193248A1 (fr) 2000-09-30 2002-04-03 Aventis Pharma Deutschland GmbH Dérivés de malonamide et d'ester malonamique possédant une activité antithrombotique, leur préparation et leur emploi
US7214690B2 (en) * 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
WO2003030937A1 (fr) * 2001-10-05 2003-04-17 Ono Pharmaceutical Co., Ltd. Remedes contre des maladies liees au stress comprenant des antagonistes de recepteurs mithochondriaux de la benzodiazepine
HRP20100067A2 (hr) * 2002-02-07 2010-04-30 University Of Tennessee Research Foundation Liječenje benigne hiperplazije prostate selektivnim modulatorima androgenih receptora
CN1646479A (zh) * 2002-02-28 2005-07-27 田纳西大学研究基金会 不可逆选择性雄激素受体调节剂及其使用方法
WO2003092588A2 (fr) * 2002-04-30 2003-11-13 Merck & Co., Inc. Derives de 4-azasteroide utilises comme modulateurs du recepteur de l'androgene
EP1562906A4 (fr) * 2002-10-15 2009-12-02 Univ Tennessee Res Foundation Modulateurs heterocycliques selectifs du recepteur des androgenes et procedes d'utilisation associes
US20040087810A1 (en) 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
TW200410921A (en) * 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
US7217794B2 (en) 2003-04-02 2007-05-15 Daiamed, Inc. Compounds and methods for treatment of thrombosis
EP1477167A1 (fr) * 2003-05-15 2004-11-17 Pfizer Limited Dérivés de [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl come agonistes de beta2
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
US7375100B2 (en) 2003-06-04 2008-05-20 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
GB0312832D0 (en) * 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
JP4585522B2 (ja) 2003-12-22 2010-11-24 メルク・シャープ・エンド・ドーム・コーポレイション ブラジキニン拮抗物質又は逆作用物質としてのアルファ−ヒドロキシアミド
BRPI0508927A (pt) * 2004-03-17 2007-08-14 Pfizer compostos úteis para o tratamento de doenças
US7629358B2 (en) 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators

Also Published As

Publication number Publication date
EP1755572B1 (fr) 2012-02-15
BRPI0511862A (pt) 2008-01-15
CR8777A (es) 2007-08-28
US20050277681A1 (en) 2005-12-15
PE20060401A1 (es) 2006-05-15
WO2005120477A3 (fr) 2006-03-02
TW200610755A (en) 2006-04-01
NZ551738A (en) 2009-11-27
US20070225229A1 (en) 2007-09-27
WO2005120477A2 (fr) 2005-12-22
ATE545631T1 (de) 2012-03-15
IL179843A0 (en) 2007-05-15
CA2569124A1 (fr) 2005-12-22
US7763659B2 (en) 2010-07-27
UA87854C2 (en) 2009-08-25
US20080139630A1 (en) 2008-06-12
SG169398A1 (en) 2011-03-30
US7268153B2 (en) 2007-09-11
EP1755572A2 (fr) 2007-02-28
US7629367B2 (en) 2009-12-08
JP4881865B2 (ja) 2012-02-22
AU2005251766B2 (en) 2009-01-15
RU2378255C2 (ru) 2010-01-10
AU2005251766B9 (en) 2009-05-28
ECSP067061A (es) 2007-01-26
AU2005251766A1 (en) 2005-12-22
MXPA06014235A (es) 2007-02-14
NO20070085L (no) 2007-03-06
MY147997A (en) 2013-02-28
AR049140A1 (es) 2006-06-28
JP2008501800A (ja) 2008-01-24
RU2006146678A (ru) 2008-07-20
CA2569124C (fr) 2013-04-23
CN1976902A (zh) 2007-06-06
ZA200609673B (en) 2008-09-25

Similar Documents

Publication Publication Date Title
MA28677B1 (fr) N-(2-benzyl) -2-phenylbutanamides modulant le recepteur d'androgene
NO20083046L (no) Polymorfer av androgenreseptormodulator (N-3H-imidazo [4,5-B] pyridin-2-yl-metyl)-2-fluor-4-metyl-3-okso-4-aza-androst-1-en-17-beta-karboksamid
WO2003092588A3 (fr) Derives de 4-azasteroide utilises comme modulateurs du recepteur de l'androgene
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
EP2037739A4 (fr) Effecteurs allostériques positifs du récepteur m1 à base de quinolone à substitution benzyle
MA33219B1 (fr) Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
AR026916A1 (es) Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales
US20200009112A1 (en) Methods and compositions for modulating hormone levels
BRPI0712976A2 (pt) uso de 2-aminotetralinas substituÍdas para a fabricaÇço de um medicamento para a prevenÇço, alÍvio e/ou tratamento de vÁrios tipos de dor
JPWO2005063241A1 (ja) ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤
WO2005005606A3 (fr) Derives 17-acetamido-4-azasteroides convenant comme modulateurs du recepteur des androgenes
MA30413B1 (fr) Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
BR9912179A (pt) Composição neuroprotetora para a prevenção e/ou tratamento de alterações nervosas e do comportamento devido a estados de ansiedade ou depressão
MD4093B1 (ro) Utilizare a compoziţiei farmaceutice topice cu conţinut de ambroxol
ATE373657T1 (de) Androgen-rezeptor-modulatoren und verwendungsverfahren dafür
WO2004100874A3 (fr) Modulateurs du recepteur d'androgenes et leur methode d'utilisation
EP1896005A4 (fr) Préparations pharmaceutiques synergiques pouvant être employées dans le traitement prophylactique et thérapeutique d'une maladie induite par la protéine bêta-amyloïde, incluant des composés dérivés de la sauge et du romarin
WO2005005380A3 (fr) Derives de 17-acetamido-4-azasteroide en tant que modulateurs du recepteur d'androgene
WO2008048540A3 (fr) 2-hydroxy-2-phényl/thiophénylpropionamides en tant que modulateurs de récepteur d'androgène
WO2005044988A3 (fr) Derives d'azasteroide-4 heterocycliques-21 en tant que modulateurs du recepteur d'androgene
WO2006026196A3 (fr) Modulateurs du recepteur de l'androgene
WO2005009949A3 (fr) Derives de 17-acetamido-4-azasteroides servant de modulateurs du recepteur d'androgenes
WO2005004807A3 (fr) Derives de 17-acetamido-4-azasteroide servant de modulateurs du recepteur d'androgenes
DOP2005000112A (es) N-(2-bencil)-2-fenilbutamidas como moduladores del receptor de androgeno